To study the effect of Habb-e-Ghafis in patients with Non-Alcoholic fatty liver disease

Evaluating the therapeutic efficacy of Habb-e-Ghafis in Non-alcoholic fatty liver disease, a randomised, single blind, standard controlled trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/01/039497

Enrollment

Registered

2022-01-17

Start date

Unknown

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Habb-e-Ghafis: Habb-e-Ghafis is a Unani pharmacopeial preparation. The preparation contains Sibr (Aloe barbadensis Mill) (exudate), Usara-e-Ghafis (Agrimonia eupatoria) (Extract of Gul-

Eligibility

Inclusion criteria

Inclusion criteria: 1. Ultrasonography (USG) documented grade 1 (mild) and grade 2 (moderate) non-alcoholic fatty liver disease. 2. Patients with dull ache/heaviness in the right hypochondriac region. 3. Patients irrespective of gender. 4. Patients in the age group of 20 to 60. 5. Body Mass Index (BMI) 6. Patients willing to sign written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients below the age of 20 years and above 60 years. 2. Grade 3 fatty liver or above. 3. Prior diagnosis of chronic liver disease other than NAFLD including autoimmune, viral and alcoholic liver disease. 4. Patients having fulminant hepatitis and drug induced hepatitis. 5. Prior diagnosis of liver cirrhosis. 6. History of liver transplantation. 7. Body Mass Index (BMI) > 35kg/m2 8. Pregnant or breastfeeding mothers. 9. Active case of malignancy. 10. Patients having cholelithiasis or cholecystitis. 11. Patients having Diabetes Mellitus. 12. Patients with cardiovascular or renal diseases. 13. Unwillingness or inability to fulfill the protocol. 14. Patients who fail to give consent.

Design outcomes

Primary

Measure	Time frame
Relief in signs and symptoms of non alcoholic fatty liver diseaseTimepoint: 45 Days	—

Secondary

Measure	Time frame
Radiological and biochemical assessment 1. Ultrasonography (USG) Abdomen/Pelvis (Liver span) 2. Liver Function Test (Sr. Bilirubin, SGOT, SGPT, ALP, Total Proteins) 3. Lipid Profile (Total cholesterol, Sr. Triglycerides, HDL, LDL, VLDL) ECG, Haematological and Biochemical assessment in view of safety evaluationTimepoint: 45 Days	—

Countries

India

Contacts

Public ContactDr Zaffar Hussain

Regional Research Institute of Unani Medicine (RRIUM)

hussainzaffar6@gmail.com7006021996

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026